Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

Compare

1,375 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IONS Analyst Ratings

Moderate Buy

14 Buy

6 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$57.37

▲(40.48% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $57.37 with a high forecast of $78.00 and a low forecast of $38.00. The average price target represents a 40.48% change from the last price of $40.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","79":"$79","39.25":"$39.3","52.5":"$52.5","65.75":"$65.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,39.25,52.5,65.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.03,45.72,48.410000000000004,51.1,53.79,56.480000000000004,59.17,61.86,64.55,67.24000000000001,69.93,72.62,75.31,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.03,44.13307692307692,45.23615384615385,46.33923076923077,47.44230769230769,48.54538461538461,49.64846153846154,50.75153846153846,51.854615384615386,52.957692307692305,54.06076923076923,55.16384615384615,56.26692307692308,{"y":57.37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.03,42.643076923076926,42.25615384615385,41.86923076923077,41.48230769230769,41.09538461538462,40.70846153846154,40.32153846153846,39.934615384615384,39.54769230769231,39.16076923076923,38.77384615384615,38.386923076923075,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$78.00

Average Price Target$57.37

Lowest Price Target$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

UBS

Not Ranked

UBS

$45→$46

Hold

12.63%

Upside

Reiterated

08/12/25

Ionis Pharmaceuticals (IONS) PT Raised to $46 at UBSUBS analyst Esther Rajavelu raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $46.00 (from $45.00) while maintaining a Neutral rating.

Mani Foroohar

Leerink Partners

$57→$56

Buy

37.12%

Upside

Reiterated

08/06/25

Leerink Partners Remains a Buy on Ionis Pharmaceuticals (IONS)

Mitchell Kapoor

H.C. Wainwright

$65

Buy

59.16%

Upside

Reiterated

08/06/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gena Wang

Barclays

$36→$57

Buy

39.57%

Upside

Reiterated

07/31/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)

Jay Olson

Oppenheimer

$78

Buy

90.99%

Upside

Reiterated

07/31/25

Oppenheimer Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

William Pickering

Bernstein

$42

Hold

2.84%

Upside

Reiterated

07/31/25

Ionis Pharmaceuticals: Hold Rating Amid Strong Performance and Future Uncertainties

Gary Nachman

Raymond James

$60→$64

Buy

56.71%

Upside

Reiterated

07/31/25

Raymond James Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)Raymond James analyst Gary Nachman raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $64.00 (from $60.00) while maintaining a Strong Buy rating.

Yanan Zhu

Wells Fargo

$77

Buy

88.54%

Upside

Reiterated

07/31/25

Ionis Pharmaceuticals: Strong Financial Performance and Strategic Growth Drive Buy Rating

Michael Ulz

Morgan Stanley

$55→$62

Buy

51.81%

Upside

Upgraded

07/31/25

Ionis Pharmaceuticals: Strong Performance and Promising Future Drive Buy Rating Upgrade

Yaron Werber

TD Cowen

$59

Buy

44.47%

Upside

Reiterated

07/30/25

TD Cowen Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

07/30/25

Ionis Pharmaceuticals: Strong Financial Performance and Promising Clinical Developments Drive Buy Rating

Joseph Stringer

Needham

$55

Buy

34.67%

Upside

Reiterated

07/30/25

Ionis Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating

Jason Gerberry

Bank of America Securities

$63

Buy

54.26%

Upside

Reiterated

07/30/25

Ionis Pharmaceuticals: Strong Q2 Performance and Promising Future Catalysts Justify Buy Rating

Luca Issi

RBC Capital

$70

Buy

71.40%

Upside

Reiterated

07/30/25

RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Allison Bratzel

Piper Sandler

$62

Buy

51.81%

Upside

Reiterated

07/28/25

Piper Sandler Remains a Buy on Ionis Pharmaceuticals (IONS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

UBS

Not Ranked

UBS

$45→$46

Hold

12.63%

Upside

Reiterated

08/12/25

Mani Foroohar

Leerink Partners

$57→$56

Buy

37.12%

Upside

Reiterated

08/06/25

Leerink Partners Remains a Buy on Ionis Pharmaceuticals (IONS)

Mitchell Kapoor

H.C. Wainwright

$65

Buy

59.16%

Upside

Reiterated

08/06/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gena Wang

Barclays

$36→$57

Buy

39.57%

Upside

Reiterated

07/31/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)

Jay Olson

Oppenheimer

$78

Buy

90.99%

Upside

Reiterated

07/31/25

Oppenheimer Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

William Pickering

Bernstein

$42

Hold

2.84%

Upside

Reiterated

07/31/25

Ionis Pharmaceuticals: Hold Rating Amid Strong Performance and Future Uncertainties

Gary Nachman

Raymond James

$60→$64

Buy

56.71%

Upside

Reiterated

07/31/25

Yanan Zhu

Wells Fargo

$77

Buy

88.54%

Upside

Reiterated

07/31/25

Ionis Pharmaceuticals: Strong Financial Performance and Strategic Growth Drive Buy Rating

Michael Ulz

Morgan Stanley

$55→$62

Buy

51.81%

Upside

Upgraded

07/31/25

Ionis Pharmaceuticals: Strong Performance and Promising Future Drive Buy Rating Upgrade

Yaron Werber

TD Cowen

$59

Buy

44.47%

Upside

Reiterated

07/30/25

TD Cowen Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

07/30/25

Ionis Pharmaceuticals: Strong Financial Performance and Promising Clinical Developments Drive Buy Rating

Joseph Stringer

Needham

$55

Buy

34.67%

Upside

Reiterated

07/30/25

Ionis Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating

Jason Gerberry

Bank of America Securities

$63

Buy

54.26%

Upside

Reiterated

07/30/25

Ionis Pharmaceuticals: Strong Q2 Performance and Promising Future Catalysts Justify Buy Rating

Luca Issi

RBC Capital

$70

Buy

71.40%

Upside

Reiterated

07/30/25

RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Allison Bratzel

Piper Sandler

$62

Buy

51.81%

Upside

Reiterated

07/28/25

Piper Sandler Remains a Buy on Ionis Pharmaceuticals (IONS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

1 Month

xxx

Success Rate

12/19 ratings generated profit

Average Return

+1.90%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +1.90% per trade.

3 Months

xxx

Success Rate

19/32 ratings generated profit

Average Return

+3.50%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.38% of your transactions generating a profit, with an average return of +3.50% per trade.

1 Year

Gary NachmanRaymond James

Success Rate

14/19 ratings generated profit

Average Return

+15.65%

reiterated a buy rating 13 days ago

Copying Gary Nachman's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +15.65% per trade.

2 Years

xxx

Success Rate

24/32 ratings generated profit

Average Return

+9.76%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +9.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IONS has received 21 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 57.37.

Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.20 with a range of -$1.38 to -$0.69. The previous quarter’s EPS was $0.70. IONS beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.79% of the time in the same period. In the last calendar year IONS has Outperformed its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $129.31M with a range of $104.00M to $172.55M. The previous quarter’s sales results were $452.05M. IONS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 53.62% of the time in the same period. In the last calendar year IONS has Outperformed its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 57.37.

What is IONS’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals has 40.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IONS a Buy, Sell or Hold?

Ionis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 14 buy ratings, 6 hold ratings and 0 sell ratings.

What is Ionis Pharmaceuticals’s price target?

The average price target for Ionis Pharmaceuticals is 57.37. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $78.00 ,the lowest forecast is $38.00. The average price target represents 40.48% Increase from the current price of $40.84.

What do analysts say about Ionis Pharmaceuticals?

Ionis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of IONS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

IONS Analyst Ratings

IONS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

IONS Analyst Recommendation Trends

IONS Financial Forecast

IONS Earnings Forecast

IONS Sales Forecast

IONS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts